Zhang 2012
Supportive Therapie · Version 2.1
|
Referenz (Autor, Jahr, Journal) |
Studientyp Mono- vs. Multizentrisch, Verblindung, Randomisierung, Arme, Fallzahl n, Land, Zeitraum |
Patientenmerkmale Indikation, Alter, Geschlecht (m/w), CTX |
Intervention |
Kontrolle |
Zielgröße |
Primary Endpoint |
Secondary Endpoint |
Finanzierung |
Evidenzstufe (CEBM levels/ SIGN) Bei Abwertung: Angabe von Gründen |
|
Zhang 2012 Ann Oncol |
Single-center, prospective randomized clinical trial N= 150 China |
stage II and III colorectal cancer ≥18 years (median age of patients in study was 56.96 years) Regimen: oxaliplatin 130 mg/m2 day 1, oral capecitabine 1000 mg/m2 2x daily or capecitabine monotherapy 1250 mg/m2 2x daily |
N= 68 Capecitabine/celecoxib group (18 patients in capecitabine/celecoxib group and 50 patients in capecitabine/oxaliplatine/celecoxib group) |
N=71 Capecitabine group (19 patients in capecitabine alone group and 52 patients in the capecitabine/oxaliplatine group) |
Primary Endpoint: Explore the ability of celecoxib to prevent HFS induced by capecitabine |
Incidence of ≥ grade 1 and ≥ grade 2 HFS: Capecitabine group and capecitabine/celecoxib (74.6% versus 57.4%, P = 0.034, 29.6% versus 14.7% P = 0.035). Grade 3 HFS (8.5% versus 2.9% P = 0.303) |
|
Research Funding: None
|
1b No placebo-controlled trial
|